Jun 10, 2024, 04:49
Ibrahim Halil Sahin: I discussed the findings of neoadjuvant rectal cancer study of Dostarlimab with Alison Kanski
Ibrahim Halil Sahin Assistant Professor of Medicine Division of Hematology/Oncology at University of Pittsburgh School of Medicine, shared a post on X:
“I discussed the findings of neoadjuvant rectal cancer study of Dostarlimab with Alison Kanski Precision Oncology News!
Immunotherapy has revolutionized the management of patients with MSI-H CRC and will continue to do so!”
Source: Ibrahim Halil Sahin/X
Alison Kanski
cancer
Cancer Management
cancer treatment
colorectal cancer
Dostarlimab
Hematology Oncology
Ibrahim Halil Sahin
immunotherapy
innovative cancer therapies
Medical Advancements
MSI-H CRC
neoadjuvant rectal cancer study
OncoDaily
Oncology
oncology discussion
oncology research
Precision Medicine
Precision Oncology News
Research
University of Pittsburgh School of Medicine